$ECOR

electroCore (ECOR) expects positive adjusted EBITDA by late 2027 without new equity financing, shifting revenue from 2026 to 2027. Cash reserves fell to $7.5M by Q3. Revenue growth was driven by VA sales of Quell Fibromyalgia and gammaCore products. The company aims to increase its national refill rate and submitted a 510(k) notification for Quell to treat CIPN. OTC Quell launch delayed due to FDA observations. Truvaga revenue declined but return on ad spend improved.

electroCore, Inc. (ECOR) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 electroCore Announces Third Quarter 2026 Financial Results Third quarter 2026 net sales of $9.7 million, an increase of 12% over $8.7 million in the third quarter of 2025 Net loss of $1.3 million decreased 61% from prior year with Adjusted EBITDA net loss improving 6

electroCore (ECOR) aims for adjusted EBITDA profitability by mid-2027, targeting federal-market expansion and product indication growth. Revenue grew at a 50% CAGR over five years, reaching $32M in 2025. The company's gammaCore device is FDA-cleared for headache treatments, and Quell, acquired in 2025, saw revenue growth post-acquisition. electroCore also filed for FDA approval of Quell for chemotherapy-induced peripheral neuropathy (CIPN).

electroCore, Inc. (ECOR) submitted a 510(k) premarket notification to the FDA seeking clearance for its Quell® device to treat chronic chemotherapy-induced peripheral neuropathy (CIPN). The submission is supported by clinical studies showing symptom improvements. If cleared, Quell would be among the first FDA-cleared devices for CIPN. The FDA review process is underway, with no guarantee of clearance.

ECOR (electroCore, Inc.) will report Q3'26 earnings on October 29. Analysts estimate revenue of $10.93M and EPS of -$0.27. The announcement is expected at 8:00 AM ET.

Errico Thomas J. purchased 5,000 shares of electroCore, Inc. (ECOR) at $9.82 on 2026-09-14.

electroCore (ECOR) shares rose 6.9% to $11.38 on higher volume. The gain follows Q2 revenue growth of 28% to $9.5M, narrowed EBITDA loss, and a raised 2026 outlook. Analysts expect a Q3 loss of $0.26 per share and 28.9% revenue growth. Stevanato (STVN) also mentioned, up 0.6% to $22.67.

electroCore, Inc. (ECOR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Exhibit 99.1 electroCore, Inc. Appoints Joshua Lev and Mike Fox as Co-Chief Executive Officers Internal leadership appointments reflect the Company’s confidence in two exceptional leaders whose complementary strengths will enhance shareholder value ROCKAWAY, N.J., September 9, 20

Ecora Royalties reported a near fourfold increase in stream revenues to $21.6mn in its half-year results, while royalties were $9.9mn. The company is shifting focus from coal to future metals, with a expected rise in metallurgical coal revenue from Kestrel in the second half.

Lev Joshua S. (CFO and Interim President) sold 20,000 shares of electroCore, Inc. (ECOR) at an average of $10.01 ($9.36–$10.22, $0.20M total) across 3 trades over 2026-08-21 to 2026-08-25.